Clinical trials: Diabetic Macular Oedema
- Condition Diabetic Macular Oedema
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Diabetic Macular Edema
Extension Study of MYL-1701P-3001 for Safety and Efficacy
This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 (NCT03610646) study.
- Trial name
- NCT04674800
- Testing
- MYL-1701P, a proposed biosimilar to Eylea
- Where
- 15 sites in India
- Volunteers
- 52 people
- Sponsor
- Mylan Pharmaceuticals Inc
Diabetic Macular Edema (DME)
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
This is a Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in comparison with Eylea in Patients with Diabetic Macular Edema
- Trial name
- NCT04739306
- Testing
- CT-P42, Eylea
- Where
- Slovakia
- Volunteers
- 348 people
- Sponsor
- Celltrion
Diabetic Macular Edema
A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study
CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to…
- Trial name
- RESTORE (NCT00687804)
- Testing
- Ranibizumab, Laser
- Where
- 13 sites in Australia, Belgium and 11 more
- Volunteers
- 345 people
- Sponsor
- Novartis
Diabetic Macular Edema
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLEAM (NCT04611152)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Germany and 6 more
- Volunteers
- 460 people
- Sponsor
- Kodiak Sciences Inc
Age-Related Macular Degeneration, Geographic Atrophy
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
To conduct a precision study to assess the microperimetry function of the Spectral OCT/SLO. The study will assess variability across measurements taken by three different operator-device configuration across clinical sites…
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema
- Trial name
- NCT01692938
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Optos, PLC
Diabetic Retinopathy
Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
The purpose of this study was to demonstrate that the change of best corrected visual acuity (BCVA) was comparable in patients treated with ranibizumab at the discretion of the investigator vs.
- Trial name
- DIVERSE (NCT02366468)
- Testing
- ranibizumab 0.5 mg
- Where
- 30 sites in Germany
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of diabetic macular edema.
- Trial name
- NCT00168389
- Testing
- Dexamethasone
- Where
- 10 sites in United States, Australia and 8 more
- Volunteers
- 494 people
- Sponsor
- Allergan
Diabetic Macular Edema
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
The purpose of this study is to demonstrate that two investigational treatment regimens have the potential to result in a superior visual acuity improvement as compared to a ranibizumab pro re nata (PRN=as needed) treatment…
- Trial name
- RETAIN (NCT01171976)
- Testing
- Ranibizumab
- Where
- 68 sites in Belgium, Czechia and 11 more
- Volunteers
- 373 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
To assess the efficacy of oral aliskiren as a therapy for diabetic macular edema
- Trial name
- NCT00768040
- Testing
- Aliskiren
- Where
- 12 sites in United States, Denmark
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W)…
- Trial name
- RHINE (NCT03622593)
- Testing
- Aflibercept, Faricimab
- Where
- 188 sites in United States, Argentina and 22 more
- Volunteers
- 951 people
- Sponsor
- Hoffmann-La Roche
Diabetic Macular Edema
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
The purpose of this clinical trial is to evaluate the safety and tolerability of suprachoroidal microcatheterization with the Oxulumis® device for a randomized treatment with two dose levels of Triesence® in subjects with…
- Trial name
- CAPE (NCT05512962)
- Testing
- Triamcinolone Acetonide, Semi-automated Suprachoroidal Microcatheter
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Oxular Limited
Diabetic Retinopathy
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
The purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes.
- Trial name
- NCT00090519
- Testing
- ruboxistaurin
- Where
- 84 sites in United States, Australia and 15 more
- Volunteers
- 731 people
- Sponsor
- Chromaderm, Inc.
Diabetes Mellitus, Macular Edema
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular…
- Trial name
- VIVID-DME (NCT01331681)
- Testing
- VEGF Trap-Eye (BAY86-5321), Macular Laser Photocoagulation (Control)
- Where
- 73 sites in Australia, Austria and 9 more
- Volunteers
- 406 people
- Sponsor
- Bayer
Diabetic Macular Edema
A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
This is a multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, three parallel group, 36-week study in participants with center-involving diabetic macular edema (DME).
- Trial name
- BOULEVARD (NCT02699450)
- Testing
- Faricimab, Ranibizumab
- Where
- 60 sites in United States
- Volunteers
- 229 people
- Sponsor
- Hoffmann-La Roche
Diabetic Macular Edema
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W)…
- Trial name
- NCT03622580
- Testing
- Aflibercept, Faricimab
- Where
- 185 sites in United States, Austria and 14 more
- Volunteers
- 940 people
- Sponsor
- Hoffmann-La Roche
Visual Impairment Due to Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema.
- Trial name
- RELATION (NCT01131585)
- Testing
- Active laser photocoagulation, Ranibizumab 0.5 mg
- Where
- 34 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema
This study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with laser treatment vs. laser treatment alone in patients with diabetic macular edema.
- Trial name
- NCT00464685
- Testing
- Dexamethasone, Laser Photocoagulation
- Where
- 2 sites in United States, Canada
- Volunteers
- 253 people
- Sponsor
- Allergan
Diabetic Macular Edema
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
This is a clinical study where patients with diabetes and a vision threatening eye condition called "Diabetic Macular Edema" receive four injections into the eye at monthly intervals.
- Trial name
- NCT03466099
- Testing
- KVD001 Injection
- Where
- 35 sites in United States
- Volunteers
- 129 people
- Sponsor
- KalVista Pharmaceuticals, Ltd.
Diabetic Macular Edema
Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema
This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.
- Trial name
- HULK (NCT02949024)
- Testing
- IVT Aflibercept, SC CLS-TA
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Clearside Biomedical, Inc.
Retinal Vein Occlusion, Age Related Macular Degeneration
Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion…
- Trial name
- NCT02140411
- Testing
- Ranibizumab Intravitreal injections
- Where
- Chile
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals